0.05 ML ranibizumab 10 MG/ML Prefilled Syringe [Lucentis]

Known as: 0.05 ML Lucentis 10 MG/ML Prefilled Syringe, Lucentis 0.5 MG per 0.05 ML Prefilled Syringe, Lucentis 0.5 MG in 0.05 ML Prefilled Syringe 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Background: Retinal Angiomatous Proliferations (RAP) is a subgroup of exsudative or “wet” Age-related Macular Degeneration (wAMD… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2013
2013
To evaluate the capability of adjuvant intraocular ranibizumab (Lucentis®) injections in the treatment of rubeosis and… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2009
2009
Retinal angiomatous proliferation (RAP) is a distinct variant of neovascular age-related macular degeneration (AMD). The aim of… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 4
  • figure 3
Is this relevant?
2008
2008
Macular choroidal neovascularization (CNV) is one of the most vision-threatening complications of myopia, which can lead to… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?